265 related articles for article (PubMed ID: 37090944)
1. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Satti SA; Sheikh MS
Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
[TBL] [Abstract][Full Text] [Related]
2. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
3. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
4. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
Kang C
Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
[TBL] [Abstract][Full Text] [Related]
5. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
8. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
[TBL] [Abstract][Full Text] [Related]
14. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
[TBL] [Abstract][Full Text] [Related]
15. Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer.
Fleming PJ; Karpio S; Lombardo N
J Adv Pract Oncol; 2021 Sep; 12(7):747-752. PubMed ID: 34671504
[TBL] [Abstract][Full Text] [Related]
16. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Spears PA; Tolaney SM
Future Oncol; 2024 Apr; 20(11):635-651. PubMed ID: 38270051
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
20. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]